Latest Avita Medical (ASX:AVH) News

Avita Medical reported an 18% revenue increase and a 30% reduction in net loss for the first half of 2025, signaling progress as it scales commercial operations and targets profitability by 2026.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

AVITA Medical has filed its Q2 2025 Form 10-Q, reaffirming its leadership in acute wound care with its FDA-approved RECELL System and expanding international footprint.

AVITA Medical’s Q2 2025 update reveals a temporary setback in RECELL demand due to Medicare reimbursement delays, offset by strong revenue growth and promising clinical data. The company anticipates recovery and renewed growth in the second half of the year.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.